Results 31 to 40 of about 14,756 (172)

Supra and subgingival application of antiseptics or antibiotics during periodontal therapy

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases (gingivitis and periodontitis) are characterized by inflammatory processes which arise as a result of disruption of the balance in the oral ecosystem. According to the current S3 level clinical practice guidelines, therapy of patients with periodontitis involves a stepwise approach that includes the control of the patient ...
Elena Figuero, Jorge Serrano, Nicole Birgit Arweiler, Thorsten Mathias Auschill, Ali Gürkan, Gülnur Emingil   +5 more
wiley   +1 more source

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)

Journal of Global Antimicrobial Resistance, 2020
Objective: To investigate possible mechanistic factors to explain cefiderocol (CFDC) non-susceptibility, we characterized 38 clinical isolates with a CFDC minimum inhibitory concentration (MIC) of >4 μg/mL from a multi-national surveillance study ...
Naoki Kohira, Meredith A. Hackel, Yoshino Ishioka, Miho Kuroiwa, Daniel F. Sahm, Takafumi Sato, Hideki Maki, Yoshinori Yamano   +7 more
doaj   +1 more source

Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors

Scientific Reports, 2022
β-lactamases are a major cause of rapidly emerging and spreading antibiotic resistance. Currently β-lactamase inhibitors (BLIs) in clinical use act only on Ambler Class A, C and some class D lactamases.
Markus Perbandt, Nadine Werner, Andreas Prester, Holger Rohde, Martin Aepfelbacher, Winfried Hinrichs, Christian Betzel   +6 more
doaj   +1 more source

OXA-23 β-Lactamase Overexpression in Acinetobacter baumannii Drives Physiological Changes Resulting in New Genetic Vulnerabilities

mBio, 2021
β-Lactamase expression is the major mechanism of resistance to penicillins, cephalosporins, and carbapenems in the multidrug-resistant (MDR) bacterium Acinetobacter baumannii.
Jennifer M. Colquhoun, Marjan Farokhyfar, Anna R. Hutcheson, Alexander Anderson, Christopher R. Bethel, Robert A. Bonomo, Anthony J. Clarke, Philip N. Rather   +7 more
doaj   +1 more source

Exploring Additional Dimensions of Complexity in Inhibitor Design for Serine β-Lactamases: Mechanistic and Intra- and Inter-molecular Chemistry Approaches

Frontiers in Microbiology, 2018
As a bacterial resistance strategy, serine β-lactamases have evolved from cell wall synthesizing enzymes known as penicillin-binding proteins (PBP), by not only covalently binding β-lactam antibiotics but, also acquiring mechanisms of deacylating these ...
Focco van den Akker, Robert A. Bonomo, Robert A. Bonomo, Robert A. Bonomo, Robert A. Bonomo   +4 more
doaj   +1 more source

Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition

Molecules, 2022
Antibacterial resistance towards the β-lactam (BL) drugs is now ubiquitous, and there is a major global health concern associated with the emergence of new β-lactamases (BLAs) as the primary cause of resistance.
Zafar Iqbal, Jian Sun, Haikang Yang, Jingwen Ji, Lili He, Lijuan Zhai, Jinbo Ji, Pengjuan Zhou, Dong Tang, Yangxiu Mu, Lin Wang, Zhixiang Yang   +11 more
doaj   +1 more source

Evaluation of inhibitory action of novel non β-lactam inhibitor against Klebsiella pneumoniae carbapenemase (KPC-2). [PDF]

PLoS ONE, 2014
The use of three classical β-lactamase inhibitors (Clavulanic acid, tazobactam and sulbactam) in combination with β-lactam antibiotics is presently the mainstay of antibiotic therapy against Gram-negative bacterial infections.
Arbab Khan, Mohammad Faheem, Mohd Danishuddin, Asad U Khan   +3 more
doaj   +1 more source

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

Antibiotics, 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann   +7 more
doaj   +1 more source

β-Lactam potentiators to re-sensitize resistant pathogens: Discovery, development, clinical use and the way forward

Frontiers in Microbiology, 2023
β-lactam antibiotics are one of the most widely used and diverse classes of antimicrobial agents for treating both Gram-negative and Gram-positive bacterial infections.
Lekshmi Narendrakumar, Medha Chakraborty, Shashi Kumari, Deepjyoti Paul, Bhabatosh Das   +4 more
doaj   +1 more source

The In vitro activity of carbapenems alone and in combination with β-lactamase inhibitors against difficult-to-treat mycobacteria; Mycobacterium tuberculosis, Mycobacterium abscessus, and Mycobacterium avium complex: A systematic review

International Journal of Mycobacteriology, 2023
Difficult-to-treat mycobacterial infections are increasing globally. There is an urgent need of new treatment alternatives for multidrug-resistant Mycobacterium tuberculosis (MTB), as well as nontuberculous mycobacteria such as the Mycobacterium ...
Viktoria Andersson, Gabrielle Fröberg, Victor Naestholt Dahl, Erja Chryssanthou, Christian Giske, Thomas Schön, Lina Davies Forsman   +6 more
doaj   +1 more source